Cabozantinib Malate 1140909-48-3 , assay 99% in GMP plant, C-GMP standard, now COA, NMR, HPLC, MS is ok.
Name: Cabozantinib malate
CAS#: 1140909-48-3 (malate)
Chemical Formula: C32H30FN3O10
Exact Mass:
Molecular Weight: 635.6014
Elemental Analysis: C, 60.47; H, 4.76; F, 2.99; N, 6.61; O, 25.17
Related CAS #: 1140909-48-3 (malate) 849217-68-1 (free base)
Synonym: XL-184; XL184; XL 184; BMS907351; BMS 907351; BMS-907351; Cabozantinib malate; Cabozantinib S-malate. Brand name: Cometriq.
IUPAC/Chemical Name: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
InChi Key: HFCFMRYTXDINDK-WNQIDUERSA-N
InChi Code: InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
SMILES Code: COC1=CC2=C(OC3=CC=C(NC(C4(C(NC5=CC=C(F)C=C5)=O)CC4)=O)C=C3)C=CN=C2C=C1OC.O=C(O)[C@@H](O)CC(O)=O
2017 China CPHI: E1M35
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
労働時間: Beijing Time 4:00AM~11:00PM
郵箱: info@eosmedchem.com; eosmedchem@gmail.com
辦公室: 0086-531-69905422-806(直通)
攜帶番號 & WhatsApp & Wechat: +8618653174435
住所: Diaozhen Chemical Industrial Park, Jinan City, China
Skype: willgutian
QQ: 2393923585
CAS#: 1140909-48-3 (malate)
Chemical Formula: C32H30FN3O10
Exact Mass:
Molecular Weight: 635.6014
Elemental Analysis: C, 60.47; H, 4.76; F, 2.99; N, 6.61; O, 25.17
Related CAS #: 1140909-48-3 (malate) 849217-68-1 (free base)
Synonym: XL-184; XL184; XL 184; BMS907351; BMS 907351; BMS-907351; Cabozantinib malate; Cabozantinib S-malate. Brand name: Cometriq.
IUPAC/Chemical Name: N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-2-hydroxysuccinate
InChi Key: HFCFMRYTXDINDK-WNQIDUERSA-N
InChi Code: InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
SMILES Code: COC1=CC2=C(OC3=CC=C(NC(C4(C(NC5=CC=C(F)C=C5)=O)CC4)=O)C=C3)C=CN=C2C=C1OC.O=C(O)[C@@H](O)CC(O)=O
1: Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res. 2015 Aug 19;7:265-78. doi: 10.2147/CMAR.S68373. eCollection 2015. Review. PubMed PMID: 26316818; PubMed Central PMCID: PMC4547654.
2: Zhang B, Zhang X, Zhou T, Liu J. Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review. Cancer Biol Ther. 2015;16(2):215-8. doi: 10.4161/15384047.2014.962318. Review. PubMed PMID: 25668362; PubMed Central PMCID: PMC4622678.
3: Fay AP, Albiges L, Bellmunt J. Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2015 Feb;15(2):151-6. doi: 10.1586/14737140.2015.1003047. Epub 2015 Jan 14. Review. PubMed PMID: 25586337.
4: Roy S, Narang BK, Rastogi SK, Rawal RK. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib. Anticancer Agents Med Chem. 2015;15(1):37-47. Review. PubMed PMID: 25181996.
5: Hoy SM. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Drugs. 2014 Aug;74(12):1435-44. doi: 10.1007/s40265-014-0265-x. Review. PubMed PMID: 25056653.
6: Nix NM, Braun K. Cabozantinib for the treatment of metastatic medullary thyroid carcinoma. J Adv Pract Oncol. 2014 Jan;5(1):47-50. Review. PubMed PMID: 25032033; PubMed Central PMCID: PMC4093460.
7: Colombo JR, Wein RO. Cabozantinib for progressive metastatic medullary thyroid cancer: a review. Ther Clin Risk Manag. 2014 May 28;10:395-404. doi: 10.2147/TCRM.S46041. eCollection 2014. Review. PubMed PMID: 24920914; PubMed Central PMCID: PMC4043815.
8: Vaishampayan UN. Development of cabozantinib for the treatment of prostate cancer. Core Evid. 2014 Apr 23;9:61-7. doi: 10.2147/CE.S48498. eCollection 2014. Review. Erratum in: Core Evid. 2014;9:69. PubMed PMID: 24790591; PubMed Central PMCID: PMC4003147.
9: Grüllich C. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Recent Results Cancer Res. 2014;201:207-14. doi: 10.1007/978-3-642-54490-3_12. Review. PubMed PMID: 24756794.
10: Pinto A. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. Cancer Chemother Pharmacol. 2014 Feb;73(2):219-22. doi: 10.1007/s00280-013-2343-2. Epub 2013 Nov 8. Review. PubMed PMID: 24202668.
11: Karras S, Pontikides N, Krassas GE. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):507-15. doi: 10.1517/17425255.2013.780028. Review. PubMed PMID: 23488614.
12: Nagilla M, Brown RL, Cohen EE. Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther. 2012 Nov;29(11):925-34. doi: 10.1007/s12325-012-0060-6. Epub 2012 Oct 25. Review. PubMed PMID: 23104465.
13: Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today (Barc). 2011 Nov;47(11):857-68. doi: 10.1358/dot.2011.47.11.1688487. Review. PubMed PMID: 22146228.
14: Durante C, Russo D, Verrienti A, Filetti S. XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011 Mar;20(3):407-413. doi: 10.1517/13543784.2011.559163. Review. PubMed PMID: 21314233.
